Aarti Drugs
Drug Manufacturers - Specialty & Generic · AARTIDRUGS
Small CapHealthcareMature Stable
Prakash M. Patil
Chairman, Managing Director & CEO · Transactional
Company DNA
Hierarchical
About
Aarti Drugs is a Small Cap company in the Healthcare sector, listed on NSE as AARTIDRUGS. With a market cap of ₹3K Cr and revenue of ₹2K Cr, it is currently in the Mature Stable phase. Known for its Hierarchical culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Mature manufacturing company with centralized leadership under long-tenured promoter management. Its strategic mandate: As an API manufacturer, the company must focus on stringent global regulatory compliance and risk mitigation to navigate global supply chain shifts.
FAQ
What kind of company is Aarti Drugs?
Aarti Drugs is a Small Cap Healthcare company (AARTIDRUGS) in the Mature Stable phase with a market cap of ₹3K Cr. It is classified as Hierarchical in culture.
What is Aarti Drugs's culture and work environment like?
Aarti Drugs has a Hierarchical culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Mature manufacturing company with centralized leadership under long-tenured promoter management.
Who leads Aarti Drugs?
Aarti Drugs is led by Prakash M. Patil (Chairman, Managing Director & CEO), a Transactional leader with 31 years of experience.
What are Aarti Drugs's financials?
Aarti Drugs reported revenue of ₹2K Cr in FY25 with a 5-year revenue CAGR of -1.6%. Operating margin: 10.3%. Market cap: ₹3K Cr.
Culture & Strategy
CultureHierarchical
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTechnical-Expert
LifecycleMature Stable
Mature manufacturing company with centralized leadership under long-tenured promoter management.
Mandate
As an API manufacturer, the company must focus on stringent global regulatory compliance and risk mitigation to navigate global supply chain shifts.
As an API manufacturer, the company must focus on stringent global regulatory compliance and risk mitigation to navigate global supply chain shifts.
Financials
Revenue FY25₹2K Cr
PAT FY25₹168 Cr
Rev CAGR 5Y-1.6%
OPM10.3%
NPM7.1%
ROE12.3%
ROCE14%
P/E15.7
Fwd P/E14.1
P/B2.3
D/E39
Mkt Cap₹3K Cr
Promoter61.2%
Institutional11.1%
Similar Culture
Could You Lead Aarti Drugs?
Take the Genome Benchmark →